Vedolizumab Shows Greater Persistence Than Tofacitinib in UC Vedolizumab Shows Greater Persistence Than Tofacitinib in UC

Vedolizumab had greater treatment persistence than tofacitinib in a retrospective study of patients with ulcerative colitis (UC) who were previously bio-naive.Medscape Medical News
Source: Medscape Gastroenterology Headlines - Category: Gastroenterology Tags: Gastroenterology Source Type: news